Cancer Research UK partners with Centella to develop radiotherapy-enhancing drug

26 May 2011

Cancer Research UK and Cancer Research Technology - the charity's development and commercialization arm - have partnered with Centella Therapeutics, a subsidiary of Varian Medical Systems (NYSE: VAR), to develop, manufacture and trial a promising new drug candidate, CEN-209 in cancer patients with solid tumors.

CEN-209, discovered at the Auckland Cancer Society Research Centre and exclusively licensed to Centella from UniServices, a wholly-owned company of The University of Auckland, New Zealand, is designed to provide benefit when used together with radiotherapy and chemotherapy to treat solid tumors. CEN-209 is the seventh drug candidate to enter Cancer Research UK's Clinical Development Partnerships (CDP) scheme.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >